Anti CD19 chimeric antigen receptor T cell therapy - Antion Biosciences

Alternative Names: Allogeneic miCAR19 T-cells - Antion Biosciences; anti-CD19 CAR T-cells - Antion Biosciences; miCAR19

Latest Information Update: 19 Jul 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antion Biosciences
Class CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

11 Jun 2024 Anti CD19 chimeric antigen receptor T cell therapy - Antion Biosciences is available for licensing as of 11 Jun 2024 (Antion Biosciences pipeline, June 2024)
22 May 2024 Early research in Autoimmune disorders in Switzerland (Parenteral)
11 Jan 2022 Allogene Therapeutics in-licenses miCAR™ technology from Antion Biosciences

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com